The global blood
screening market is expected to reach a value of USD 3.9 billion
by 2024, based on a new report by Grand View Research, Inc. The growth of the
market is attributed to the increasing screening of donor and continuous
technological advancements by the market players. Demand for blood screening
tests are increasing continuously due to increasing donation, rising awareness
about transfusion-transmitted diseases, and technological developments in the
industry.
Thorough screening is necessary for all donated blood
to ensure that recipients receive the safest products. As of 2015, such testing
consists of screening for red cell antibodies, and the infectious diseases
agents: HIV-1, HIV-2, hepatitis virus, West Nile Virus (WNV), Human
T-Lymphotropic Virus (HTLV) T. Cruzi, and T. pallidum (syphilis).
Result of all these assays must be negative for blood donation.
Technological developments in the market increase the
sensitivity and efficiency of the tests. For instance, in 2016, the U.S. FDA
approved the Procleix Zika virus assay from Hologic, Inc. and Grifols to screen
donated blood. Furthermore, the U.S. FDA approved next-generation sequencing
(NGS) technology in 2013. The technology is cheaper and faster than previous
DNA analysis methods.
Browse full research report on Blood Screening Market: https://www.grandviewresearch.com/industry-analysis/blood-screening-market
Further Key Findings from the Study Suggest:
- Nucleic acid amplification test or nucleic acid test (NAT) is
expected to be the fastest growing segment during the forecast period. It
comprises transcription mediated amplification (TMA) tests and polymerase
chain reaction. Increasing demand of NAT over ELISA test due to high
sensitivity and specificity for viral nucleic acid is contributing to the
fastest growth during the forecast period.
- In 2015, reagent dominated the product segment. Introduction of new
assays for the detection of various diseases is expected to enable the
segment to gain the maximum share of market in the coming years. For
instance, in January 2015 the FDA approved Roche’s blood screening assay
COBAS TaqScreen MPX Test for the detection and identification of HCV, HIV,
and HBV.
- In 2015, regionally North America dominated with a revenue share of
more than 40%. Government initiatives, presence of major players, and more
patient affordability are the major factors that contributed toward its
dominance.
- In August 2016, the FDA recommended the testing of all the donated
blood in the U.S. and its territories for Zika virus in order to prevent
transmission of this virus through the blood supply.
- Asia Pacific is expected to be the fastest growing region due to
increasing investment of industry players, government initiatives, and
rising awareness about transmission of diseases during its transfusion.
- The Red Cross in Japan entered into a contract with Grifols for
nucleic acid testing (NAT) for a blood donation camp in Japan in 2014.
This agreement is anticipated to propel the NAT market during the forecast
period. However, low donation as compared to requirement and high cost of
kits and instruments are likely to restrain the growth in low-income
countries during the forecast period.
Browse more reports of this category
by Grand View Research: https://www.grandviewresearch.com/industry/clinical-diagnostics
Grand
View Research has segmented the blood screening market by technology, product
and region:
Blood
Screening Market Technology Outlook (Market Revenue in USD Million, 2013 -
2024)
- Nucleic Acid
Amplification Test (NAT)
- ELISA
- Chemiluminescence
Immunoassay (CLIA) and Enzyme Immunoassay (EIA)
- Next-Generation
Sequencing (NGS)
- Western
Blotting
Blood
Screening Market Product Outlook (Market Revenue in USD Million, 2013 -
2024)
- Reagent
- Instrument
Blood
Screening Market Regional Outlook (Market Revenue in USD Million,
2013 - 2024)
- North America
- U.S.
- Canada
- Europe
- UK
- Germany
- Asia Pacific
- Japan
- China
- Latin America
- Brazil
- Middle East
and Africa
- South Africa
About Grand View
Research
Grand View Research, Inc. is a U.S. based market
research and consulting company, registered in the State of California and
headquartered in San Francisco. The company provides syndicated research
reports, customized research reports, and consulting services. To help clients
make informed business decisions, we offer market intelligence studies ensuring
relevant and fact-based research across a range of industries, from technology
to chemicals, materials and healthcare.
No comments:
Post a Comment